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INTRODUCTION: 
Transmucosal routes of drug delivery (i.e., the mucosal 
linings of the nasal, rectal, vagina, ocular and oral cavity) 
offer distinct advantages over peroral administration for 
systemic drug delivery. These advantages includes 
possible bypass of the first pass effect, avoidance of pre-
systemic elimination of gastro intestinal tract and 
depending on the particular drug. The nasal cavity as a site 
for local and systemic drug delivery has been investigated 
by many research groups1-4 and the route has already 
reached commercial status with several drugs including 
calcitonin5, 6. However, the potential irritation and 
irreversible damage to the ciliary action application of 
nasal dosage forms, as well as the large intra and inter 
subject variability in mucus secretion in the nasal mucosa 
could significantly effect drug absorption from this site.  
 
Currently, many nasal drug products on the market are 
indicated for the treatment of local disease such as allergic 
rhinitis, pain and for centrally acting drugs where the 
direct pathway from the nose to brain might offer a 
quicker and further specific therapeutic effect. Many low-
molecular-weight, non-polar drugs (<300Da) in solution 
form are able to infiltrate the nasal epithelium with 
effortlessness. The effectiveness of a particular delivery 
system is also affected by its formulation as a liquid7, 
powder7, gel8, microsphere9, liposome10 or nanoparticle11. 
Intranasal drug delivery is now recognized to be a useful 
and reliable alternative to oral and parenteral routes. In 
general, among the primary targets for intranasal 
administration are pharmacologically active compounds 
with poor stability in gastrointestinal fluids, poor intestinal 
absorption and/or extensive hepatic first-pass elimination, 
such as peptides, proteins and polar drugs 12.  
The nasal delivery seems to be a favorable way to 
circumvent the obstacles for blood-brain barrier (BBB) 
allowing the direct drug delivery in the biophase of central 
nervous system (CNS)-active compounds. In addition, 
intranasal absorption avoids the gastrointestinal and 
hepatic pre-systemic metabolism, enhancing drug 
bioavailability in comparison with that obtained after 
gastrointestinal absorption13, 14. Hence, it appears to be an 
appropriate route for the treatment of not only acute or 
chronic nasal diseases, but also for a range of acute or 
chronic conditions requiring considerable systemic drug 
exposure 12. Since building a more efficient nasal drug 
delivery device requires not only better device design but  
a far more versatile technology platform; one that delivers 
optimal nasal deposition, with formulation flexibility to 
work successfully with the many variables of the 
formulation itself. Present review focuses on the 
innovations in nasal drug delivery devices. Additionally 
this review also outlines anatomical and physiological 
features of nasal cavity, the major factors affecting nasal 
drug delivery.  
 
REASON FOR DEVELOPMENT OF NASAL 
DELIVERY 
Nasal drug delivery is a useful delivery method for drugs 
that are active in low doses and show no or minimal oral 
bioavailability. The nasal route circumvents hepatic first 
pass elimination associated with the oral delivery: it is 
easily accessible and suitable for self-medication. 
Currently, tow classes of nasally delivered therapeutics are 
on the market. The first one comprises low molecular 
weight and hydrophobic drugs for the treatment of the 
nasal mucosa and sinus, including decongestants, topical 
steroids, antibiotics and other (OTC) products. The second 
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class encompasses a few drugs, which have sufficient 
nasal absorption for displaying systemic effects. Important 
candidates are the compounds, generally administered by 
injection and hardly absorbed after oral administration, 
due to their instability in gastrointestinal tract, poor 
absorption properties, and their rapid and extensive 
biotransformation15-17.  
 
 
Table 1: Benefits of nasal drug delivery comparison to alternate delivery methods12-14 
Key Features Nasal Oral I.V. 
High Drug Level Yes No Yes 
Rapid Onset Yes No Yes 
Painless Yes Yes No 
Self Administration Yes Yes No 
Low Resource Utilization Yes Yes No 
Bypasses BBB Yes No No 
Patient Compliance High Low High 
Hepatic First Pass Metabolism No Yes No 
After Taste Low No High 
Peptide drug Degradation Low High No 
Emesis No Yes No 
  
MECHANISM OF DRUG ABSORPTION 
THROUGH NASAL MUCOSA: 
The first step in the absorption of drug from the nasal 
cavity is passage through the mucus16. Small, unchanged 
particles easily pass through this layer. However, large or 
charged particles may find it more difficult to cross. 
Mucin, the principle protein in the mucus, has the 
potential to bind to solutes, hindering diffusion. 
Additionally, structural changes in the mucus layer are 
possible as a result of environmental changes (i.e. pH,  
 
 
temperature, etc.)18. Subsequent to a drug‟s passage 
through the mucus, there are several mechanisms for 
absorption through the mucosa 19. These include 
transcellular or simple diffusion across the membrane, 
paracellular transport via movement between cell and 
transcytosis by vesicle carriers18. Obstacles to drug 
absorption are potential metabolism before reaching the 
systemic circulation and limited residence time in the 
cavity.
 
 
Figure 1: (A) Paracellular route (A1) Intercellular spaces, (A2) Tight junctions, (B) Transcellular route (B1) Passive 
diffusion, (B2) Active transport, (C) Transcytosis 
 
The first mechanism involves an aqueous route of 
transport, which is also known as the paracellular route 
(Figure 1). This route is slow and passive. Insulin, 
mannitol and propranolol were absorbed through this 
mechanism. There is an inverse log-log correlation 
between intranasal absorption and the molecular weight of 
water-soluble compounds. Literature survey revealed that 
good bioavailability was observed for drugs with a 
molecular weight up to 1000 Daltons. But with the help of 
permeation enhancers good bioavailability can be 
enhanced to at least 6000 Daltons20. The second 
mechanism involves transport through a lipoidal route that 
is also known as the transcellular process and is 
responsible for the transport of lipophilic drugs that show 
a rate dependency on their lipophilicity. Drugs also cross 
cell membranes by an active transport route via carrier-
mediated means or transport through the opening of tight 
junctions22. For example, Chitosan, a natural biopolymer 
from shellfish, opens tight junctions between epithelial 
cells to facilitate drug transport21. 
 
RECENT NASAL DRUG DELIVERY DEVICES 
AND TECHNIQUES: 
Building a more efficient nasal drug delivery device 
requires not only better device design but  a far more 
versatile technology platform; one that delivers optimal 
nasal deposition, with formulation flexibility to work 
successfully with the many variables of the formulation 
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itself. Drug formulation and delivery devices can be 
mutually adapted and matched for optimal characteristics 
to reach the desired therapeutic target. 
 
A. ChiSys™ Nasal Delivery22: 
West Drug Delivery of Lionville, Pa (US) and 
Nottingham, UK, have developed ChiSys, a patent 
protected versatile transmucosal delivery system based on 
the bioadhesive excipient chitosan. Chitosan is an 
interesting and versatile molecule, as it has been used 
extensively in a number of field ranging from wound-
healing, slimming aid and cosmetics to a wastewater 
treatment flocculent. Recently, chitosan has been the 
subject of interest in a number of pharmaceutical and drug 
delivery studies, as evidenced by its many appearances in 
literature. West believes chitosan works well as a 
bioadhesive excipient; it is theorised that its positively 
charged molecules interact with the negatively charged 
sialic acid residues present in mucus, thereby retaining 
drug compound at the mucosal surface for an extended 
period of time. 
 
B. DirectHalerTM Technology23: 
Direct-Haler A/S has invented and developed a novel 
nasal delivery device and nasal delivery principle. The 
innovation takes advantage of the patient‟s anatomy to 
improve nasal delivery effectiveness and convenience. 
The integrated nasal device and delivery method enables 
nasal delivery of very fine particles, without the risk of 
pulmonary deposition. The DirectHaler Nasal device has 
successfully been used in clinical trials, and has confirmed 
patient acceptability. The single-use, disposable device is 
for both mono and bi-dose delivery, in a pre-metered, 
prefilled dose format. The device offers effective, 
accurate, repeatable and hygienic dosing, and is intuitively 
easy-to-use (Figure 2).  
 
Figure 2: DirectHaler Nasal: Device innovation and delivery method innovation23 
 
How DirectHaler deliver the drug? 
When air is being blown out of the mouth against a 
resistance, the airway passage between the oral and nasal 
cavities automatically closes. The same reflex is activated 
when a person blows up a balloon; none of the air escapes 
through the nose. This anatomical feature is activated 
when the patient uses DirectHaler Nasal for blowing their 
nasal dry-powder dose into their nostril. Thus, the dose is 
captured in the nasal cavity, where it is intended to act or 
to be absorbed into the systemic circulation. After 
completion of the dose delivery blow, the nasal/oral 
connection returns to its normal open state. 
 
 
 
Figure 3: BiDirectional Nasal delivery25 
 
C. Bi-Directional Nasal Delivery24-26: 
Bi-directional nasal delivery devices offer a unique 
solution for nasal delivery of drugs and vaccines. Bi-
directional delivery devices improve distribution to the 
nasal mucosa in general and can target the sinus ostia and 
organized nasal lymphatic tissues, while at the same time 
preventing lung deposition. Breath actuation and 
controlled particle release secure a reliable, efficient and 
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safe delivery of vaccines to the target sites within the nasal 
passages with maximum patient comfort. Breath Powered, 
Bi-directional Delivery consists of a mouthpiece and a 
sealing nozzle;  
 Blowing into the device cause the soft palate to 
close, isolating the nasal cavity 
 As the patient continues to blow the device is 
triggered, releasing drug into the air flow and 
carrying it deep into the nasal cavity 
 At the back of the nose, the air flow passes through a 
communication between the nasal passages and exits 
through the other nostril in the opposite direction  
By permitting delivery of nasal formulation to the target 
sites in the nose, benefits can be gained from increased 
absorption and lower dose. Any dispersion technology for 
liquid and powder particles can be combined with the bi-
directional nasal delivery concept, adding to its versatility 
(Figure 3, 4). 
 
 
 
Figure 4: Target sites that are better served by bi-directional delivery24 
 
Deposition studies of bi-directional delivery using gamma 
scintigraphy have shown significantly improved deposition 
patterns compared with traditional nasal spray pumps. 
Phase I nasal vaccination trials have shown a several fold 
increase in the immune response as compared with vaccine 
delivery by traditional spray devices. Patient acceptance 
and compliance for the bi-directional device are excellent 
thanks to the two-point device fixation and breathe 
actuation. Bidirectional delivery can be useful in vaccine 
delivery, topical and systemic nose to brain delivery. 
 
D. CONTROLLED PARTICLE 
DISPERSION(CPD)™:27 
Controlled Particle Dispersion (CPD) is a technology 
platform that pharmaceutical companies can use to deliver 
most compounds regardless of characteristics or target 
conditions. Whether the applications are systemic or 
topical, solutions or suspensions, CPD meets the demands 
of today and tomorrow‟s full nasal delivery product line. 
CPD offers a vast improvement in efficacy and 
performance while presenting design flexibility for 
maximum compliance. Rather than build a single device, 
Kurve Technology developed CPD – a comprehensive 
nasal drug delivery technology platform. Using new 
principals such as vortical flow, CPD effectively disrupts 
inherent nasal cavity airflows to deliver compounds to the 
entire nasal cavity, the olfactory region and the paranasal 
sinuses. CPD optimizes droplet size and trajectory to 
saturate the nasal cavity, lengthens compound residence 
time, and minimizes deposition to the lungs and stomach. 
This leads to more effective and efficient treatments than 
delivery via traditional nasal spray bottles that deliver 
compounds only as far as the anterior portion of the nasal 
cavity. 
 
CPD’s adjustable variables include: 
 Droplet size variability from 3 to 50 μm 
 Atomization rate 
 Delivery of solutions, suspensions and dry powder 
 Small and large molecules, Proteins and peptides 
 Preservative-free, unit-dose ampoules 
 Targeted deposition including to the paranasal sinuses 
and the olfactory region 
 Variable medication volumes in the device and in the 
nasal cavity 
 Wide viscosity range 
E. Advanced nasal spray medications: 
They are simple and easy to administer, noninvasive and 
virtually pain free method for nasal drug delivery. Other 
benefits of advanced nasal spray: 
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 Reduce irritation as they are preservative-free 
 Demonstrate rapid onset of action and efficient 
absorption 
 Provide for precise, metered doses  
 Enable greater patient compliance 
Nasal sprays are an alternative to injections because they 
eliminate needles and the associated risk of contamination 
from blood. Also, while only a trained health professional 
can perform an injection, patients, caregivers and 
professionals can readily use nasal sprays with minimal 
instruction or assistance. Compared to oral, sublingual and 
sometimes intramuscular injections, drugs administered 
nasally are absorbed more quickly. 28 
Orally administered drugs like midazolam and 
hydromorphone tend to be rapidly metabolized by the 
intestinal tract and liver and have greater variability in their 
absorption and bioavailability than nasally delivered drugs. 
ITI (Ikano therapeutics Inc.) studies show that smaller 
doses of the same two nasally administered drugs produce 
faster absorption rates and bioavailability yet with similar 
plasma concentrations as the orally delivered forms. 
Gastrointestinal-related side effects may also be reduced 
because nasally delivered medication bypasses the gut59. 
ITI products improve the likelihood that patients will take 
regular and accurate doses of their medication because 
nasal devices are compatible with active lifestyles and 
reduce the potential for waste and abuse28. 
 
F. MAD Nasal-Mucosal Atomizer: 
MAD Nasal-Mucosal Atomization Device delivers 
intranasal medication in a fine mist which enhances 
absorption and improves bioavailability for fast and 
effective drug delivery. By eliminating the need to establish 
an IV, delivery is rapid which is useful for treating various 
emergencies, ENT, anesthesia and pediatric conditions29 
(Figure 5). 
 
Figure 5: MAD Nasal-Mucosal Atomization Device 29 
 
MAD Nasal Features and Benefits: 
No needle - No shot → Safe and Painless 
Medications absorb directly into the brain via olfactory 
mucosa → Rapidly Effective  
Exact dosing, exact volume, Atomizes in any position → 
Controlled administration 
Drug administration is quick, No sterile technique is 
required → Minimal Resource Utilization 
 
G. NasoNeb™ Nasal Nebulizer30 
A new double barrel atomization device from ASL 
Pharmacy® offers hope for chronic sinusitis patients. The 
NasoNeb™ Nasal Nebulizer may be used for the 
administration of compounded tobramycin, clarithromycin, 
mupirocin, meropenem and other antibiotics, anti-fungals, 
mucolytics and corticosteroids (Figure 6).  
 
 
Figure 6:  NasoNeb™ Nasal Nebulizer30 
 
H. Preservative Free Systems (P.F.S.) 61 
Preservatives are commonly used in drug formulations and 
they are generally well tolerated when used in small 
amounts for occasional treatments. However in the case of 
nasal spray delivery, preservatives can be irritating to the 
patient mucosa causing some unpleasant itching, but more 
seriously can also slow down or even stop the mucociliary 
clearance which is an essential natural mechanism for the 
protection of the upper airways.  
Preservatives can also make the work of the formulation 
scientist more challenging by causing some 
stability/compatibility issues, and/or by modifying the smell 
and/or taste of the drug product.  
To help formulation scientists reduce and eliminate 
preservatives from nasal spray formulations, drug delivery 
device manufacturers have successfully developed and 
marketed specific multidose spraying devices called 
Preservative Free Systems (P.F.S.).  
There are two main categories of technologies currently 
used for P.F.S: 
Fully sealed systems: This technology was developed by 
Valois Pharma. The pumps are non-vented which means 
contamination from the environment cannot enter the 
container- by design - and come into contact with the drug 
product. In addition specific actuators equipped with a 
mechanical tip seal prevents contamination of the 
formulation in the actuator between actuations  
Vented pumps equipped with a micro-filter: Several 
manufacturers are using this technology. These pumps are 
designed in such a way that the air is sterile-filtered at the 
inlet via the micro-filter. These pumps are also used in 
conjunction with specific self-sealing valves in the actuator 
tip. An alternative approach is to use a specific actuator 
with a bacteriostatic material (generally silver derivatives or 
ions) that is released into the drug formulation in the 
actuator tip.  
 
NEEDS AND FUTURE PROSPECTIVE OF NASAL 
DRUG DELIVERY TECHNOLOGIES: 
In the field of drug delivery, drug delivery technologies will 
play a key role in the success or failure of the industry. The 
need for non-invasive delivery systems continues due to 
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patients‟ poor acceptance and compliance with existing 
delivery regimes, limited market size for drug companies 
and drug uses, coupled with high cost of disease 
management. The current needs of the industry are 
improved solubility/stability, biological half-life and 
bioavailability enhancement of poorly absorbed drugs. Key 
issues facing the biopharma industry are to improve safety, 
improve efficacy for organ targeting, and improved 
compliance via sustained release or increasing residence 
time of drug at the site of application.  New technologies 
include improved nasal formulations; site specific release, 
carrier-based systems, advanced spray formulations, 
atomized mist technology, preservative free system and 
integrated formulation development are strictly needed for 
success of drug delivery through nasal mucosa. 
For success of nasal drug delivery Researchers may focus 
on:  
 Development of delivery technologies to increase 
efficacy and reduce side effects by target delivery with 
variations potential of the drug 
 Development of new technologies to deliver 
macromolecules with utilization of biotechnology and 
high technology  
 Development of integrated/improved nasal 
formulations 
 Development of integrated device development for  
successful delivery of therapeutics 
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